Rungsinee Phongpradist, Chuda Chittasupho, Siriporn Okonogi, Teruna Siahaan, Songyot Anuchapreeda, Chadarat Ampasavate and Cory Berkland Pages 2321 - 2330 ( 10 )
Leukemia therapeutics are aiming for improved efficacy by targeting molecular markers differentially expressed on cancerous cells. Lymphocyte function-associated antigen-1 (LFA-1) expression on various types of leukemia has been well studied. Here, the role and expression of LFA-1 on leukemic cells and the possibility of using this integrin as a target for drug delivery is reviewed. To support this rationale, experimental results were also included where cIBR, a cyclic peptide derived from a binding site of LFA-1, was conjugated to the surface of polymeric nanoparticles and used as a targeting ligand. These studies revealed a correlation of LFA-1 expression level on leukemic cell lines and binding and internalization of cIBR-NPs suggesting a differential binding and internalization of cIBR-NPs to leukemic cells overexpressing LFA-1. Nanoparticles conjugated with a cyclic peptide against an accessible molecular marker of disease hold promise as a selective drug delivery system for leukemia treatment.
HL-60 cell line,LFA-1,leukemia,Molt-3 cell line,Molt-4 cell line,peptide,nanoparticles,targeting,U937 cell line
, , , , , , Department of Pharmaceutical Chemistry and Chemical and Petroleum Engineering, 2030 Becker Drive, Lawrence, Kansas 66047.